Strontium Ranelate
Based on 2 publication(s) in Google Scholar
Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate can also activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.30%
- CAS No.: 135459-87-9
- 화학식: C12H6N2O8SSr2
- 분자량:513.49
-
보관:
4°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Strontium Ranelate
More
Biological Activity
Strontium Ranelate (0.1-1 mM; 22 days; Mouse calvaria cells) treatment shows the expression of mRNA for early osteoblast markers (alkaline phosphatase, ALP) is visualized by day 5, while late markers (osteocalcin, OCN) are detectable only by day 15 and beyond[1].
Strontium Ranelate (0.1-1 mM; 22 days; Mouse calvaria cells) treatment results in significantly increases the mRNA expression of the osteoblastic markers ALP, BSP and OCN at day 22 of MC cell culture[1].
Strontium Ranelate is found to increase alkaline phosphatase activity and prostaglandin E2 production in a COX-2 dependent manner in murine marrow stromal cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Mouse calvaria (MC) cells
-
Concentration:0.1 mM, 0.3 mM or 1 mM
-
Incubation Time:22 days
-
Result:The expression of mRNA for early osteoblast markers (ALP) was visualized by day 5, while late markers (OCN) were detectable only by day 15 and beyond.
-
Cell Line:Mouse calvaria (MC) cells
-
Concentration:0.1 mM, 0.3 mM or 1 mM
-
Incubation Time:22 days
-
Result:Significantly increased the mRNA expression of the osteoblastic markers ALP, BSP and OCN at day 22 of MC cell culture.
In intact adult rats, Strontium Ranelate also increases bone mass, as measured by dual-energy X-ray absorptiometry, in lumbar vertebra and femur, and this is confirmed by histological assessment of trabecular bone volume in the tibial metaphysis[2].
Strontium Ranelate is found to decrease bone resorption and to increase bone formation in alveolar bone in normal adult monkeys (Macaca fascicularis), which exhibits extensive bone remodeling[2].
In ovariectomized rats, short-term (3 months) treatment with Strontium Ranelate prevents trabecular bone loss induced by oestrogen deficiency, as demonstrated by bone ash, bone mineral content and histomorphometric analysis in the tibial metaphysis. This effect results from decreased bone resorption while bone formation was maintained. These beneficial effects of Strontium Ranelate on bone mass and microarchitecture in ovariectomized rats are confirmed in long-term experiments. In this long-term study (2 years), the increase in bone mass and microarchitecture induced by Strontium Ranelate results in a marked improvement in bone strength, supporting the beneficial effect of this drug on bone resistance[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 135459-87-9
-
Appearance Solid
-
분자량 513.49
-
화학식 C12H6N2O8SSr2
-
Color Light yellow to yellow
-
SMILES
O=C(O[Sr]OC(C1)=O)C2=C1C(C#N)=C(N3CC(O[Sr]OC(C3)=O)=O)S2
-
Synonyms
Distrontium renelate; S12911
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Biosci Rep
The effect of strontium ranelate on titanium particle-induced periprosthetic osteolysis regulated by WNT/β-catenin signaling in vivo and in vitro. [Abstract]2021 Jan 29;41(1):BSR20203003. PMID: 33443286 -
용액&용해도
0.1 M HCl : 17.5 mg/mL (34.08 mM; ultrasonic and adjust pH to 3 with HCl)
H2O : 2 mg/mL (3.89 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: Saline
Solubility: 2 mg/mL (3.89 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
순도&문서
-
Data Sheet (284 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Bonnelye E, Chabadel A, Saltel F, Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2008 Jan;42(1):129-38. Epub 2007 Sep 12. [Content Brief]
[2]. Marie PJ. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr Opin Rheumatol. 2006 Jun;18 Suppl 1:S11-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / 0.1 M HCl | 1 mM | 1.9475 mL | 9.7373 mL | 19.4746 mL | 48.6864 mL |
| 0.1 M HCl | 5 mM | 0.3895 mL | 1.9475 mL | 3.8949 mL | 9.7373 mL |
| 10 mM | 0.1947 mL | 0.9737 mL | 1.9475 mL | 4.8686 mL | |
| 15 mM | 0.1298 mL | 0.6492 mL | 1.2983 mL | 3.2458 mL | |
| 20 mM | 0.0974 mL | 0.4869 mL | 0.9737 mL | 2.4343 mL | |
| 25 mM | 0.0779 mL | 0.3895 mL | 0.7790 mL | 1.9475 mL | |
| 30 mM | 0.0649 mL | 0.3246 mL | 0.6492 mL | 1.6229 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Strontium Ranelate Related Classifications
HY-17397 Related Classifications
Powered by Bioz